Patrick Truesdell - 16 May 2022 Form 3 Insider Report for Landos Biopharma, Inc.

Role
Vice President and Controller
Signature
/s/ Patrick Truesdell
Issuer symbol
N/A
Transactions as of
16 May 2022
Net transactions value
$0
Form type
3
Filing time
26 May 2022, 08:28:34 UTC
Next filing
02 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LABP Employee Stock Option (right to buy) 16 May 2022 Common Stock 90,000 $0.8700 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as to one-fourth (1/4th) of the shares subject to the option on May 3, 2023, and remainder shall vest in thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.